Aprindine reduced the total number of ventricular extrasystoles by 50% or more in 54% of patients, compared to 50% with mexiletine, demonstrating comparable clinical efficacy.
RCT (n=22)
Envelope method
Yes
Does aprindine reduce ventricular extrasystoles compared to mexiletine in patients with frequent ventricular extrasystoles?
Aprindine is as effective as mexiletine in suppressing ventricular extrasystoles but strongly suppresses cardiac conduction systems and requires monitoring for liver function abnormalities.
Absolute Event Rate: 54% vs 50%
p-value: p=Not significant
Purpose: A comparison study was Preformed for the clinical effects of aprindine (AP) on ventricular extrasystole in the same patient, using mexiletine (MX) as a control, by a cross-over method that used the envelope method.Method: Twenty-two patients from nine facilities with ventricular extrasystole of 5, 000/day or more were administered AP 40mg/day and MX 300mg/day.Prior to treatment and at the completion of each treatment, recordings of DCG, electrocardiogram at rest, and measurements of blood concentration were carried out.Results: A reduction rate of 50% or more in the total number of extrasystoles was observed in 12 patients (54%) administered AP, in 11 administered MX (50%), and although a Lown classification of IV or higher was observed in 16 patients, it improved to III or less in eight AP patients and in seven MX patients. In an analysis by the Lerenz plot method, the coupling interval was prolonged significantly by the administration of AP. The PQ interval and QRS width also were prolonged significantly by the administration of AP.Conclusion: AP was considered to be a drug that strongly suppresses conducting systems of the heart, especially atrial and intraventricular conduction.
Ozawa et al. (Wed,) conducted a rct in Ventricular extrasystole (n=22). Aprindine vs. Mexiletine (300 mg/day) was evaluated on Reduction rate of 50% or more in the total number of extrasystoles (p=Not significant). Aprindine reduced the total number of ventricular extrasystoles by 50% or more in 54% of patients, compared to 50% with mexiletine, demonstrating comparable clinical efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: